Travere’s Filspari reduces urine protein levels in adults with IgAN

Travere’s Filspari reduces urine protein levels in adults with IgAN

Source: 
Clinical Trials Arena
snippet: 

San Diego-based Travere Therapeutics announced positive interim results from a Phase III trial investigating Filspari (sparsentan) in adults with IgA nephropathy (IgAN), a rare progressive kidney disease. Filspari is a selective dual-acting receptor antagonist indicated to reduce proteinuria in adults with IgAN.